Neuro-focused Arkuda raises $64M as dementia drug moves closer to the clinic
Eli Lilly is among the new investors joining the Series B round of Arkuda Therapeutics, a biotech developing a drug to treat a rare, inherited form of dementia. If the biotech’s approach works, it could also have applications in other neurodegenerative conditions such as Alzheimer’s and Parkinson’s.